Nuvalent, Inc. 4

Sapna Srivastava tendered 5,146 Nuvalent Class A shares at $124.00 and had 3,444 RSUs plus options on 115,436 shares cashed out and cancelled in the GSK merger.

On July 15, 2026, in connection with the cash acquisition of Nuvalent, Inc. by GlaxoSmithKline LLC, reporting person Sapna Srivastava tendered and had cancelled 5,146 shares of Class A Common Stock for $124.00 per share in cash, and all of her equity awards were cashed out and terminated. Specifically, 3,444 time-based restricted stock units were cancelled and converted into the right to receive a cash payment based on the $124.00 offer price, and five tranches of stock options covering an aggregate 115,436 shares (exercise prices $17.00, $9.36, $44.68, $80.03 and $75.53, with expirations from 2031 to 2035) were cancelled in exchange for cash equal to the spread, if any, between the $124.00 offer price and the respective exercise prices. Following consummation of the tender offer and merger, Srivastava reported zero shares of Nuvalent Class A Common Stock owned directly, reflecting the company’s transition to a wholly owned subsidiary of GlaxoSmithKline and the full cash-out of her equity position.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305082

Alert Tier

6